Abstract

Autoantibodies toward clotting factors may develop in people suffering from autoimmune or neoplastic diseases, after drug intake or even in subjects without apparent conditions. They are more commonly directed against factor VIII (FVIII) or von Willebrand factor leading to acquired hemophilia A or acquired von Willebrand syndrome, respectively. Rarely, autoantibodies develop against other clotting factors, such as fibrinogen, FII, FV, FVII, FX, FXI, and FXIII. The clinical picture of an acquired bleeding disorder includes a wide spectrum of clinical manifestations ranging from minimal or no bleeding to life-threatening events. Patients with no previous personal or family history of bleeding may have sudden-onset hemorrhagic manifestations, sometimes fatal, especially if an early diagnosis is not made. On the other hand, some patients may not have hemorrhagic symptoms at onset, and their diagnosis can therefore be delayed. The laboratory diagnostic assessment is performed by screening coagulation tests followed by specific factor-level measurement and inhibitor-titrating assays. An early diagnosis of acquired coagulopathies is mandatory for starting the appropriate treatment aimed at both controlling the acute bleeding episode mainly using the bypassing agents, and eradicating the anticlotting factor autoantibody, using immunosuppressive treatment. Therefore, prompt intervention by an expert and a specialized center is needed for immediate recognition and treatment of the disease.

References

References
1.
Furie
B
,
Furie
BC
.
Molecular and cellular biology of blood coagulation
.
N Engl J Med
.
1992
;
326
(
12
):
800
-
806
.
2.
Palla
R
,
Peyvandi
F
,
Shapiro
AD
.
Rare bleeding disorders: diagnosis and treatment
.
Blood
.
2015
;
125
(
13
):
2052
-
2061
.
3.
Ahmed
AE
.
Autoantibodies to coagulation factors and bleeding disorders
.
Clin Rev Allergy Immunol
.
1998
;
16
(
3
):
313
-
319
.
4.
Miller
CH
.
Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review
.
Haemophilia
.
2018
;
24
(
2
):
186
-
197
.
5.
Knoebl
P
,
Marco
P
,
Baudo
F
, et al
;
EACH2 Registry Contributors
.
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
.
J Thromb Haemost
.
2012
;
10
(
4
):
622
-
631
.
6.
Franchini
M
,
Vaglio
S
,
Marano
G
, et al
.
Acquired hemophilia A: a review of recent data and new therapeutic options
.
Hematology
.
2017
;
22
(
9
):
514
-
520
.
7.
Franchini
M
,
Castaman
G
,
Coppola
A
, et al
;
AICE Working Group
.
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management
.
Blood Transfus
.
2015
;
13
(
3
):
498
-
513
.
8.
Paddock
M
,
Chapin
J
.
Bleeding diatheses: approach to the patient who bleeds or has abnormal coagulation
.
Prim Care
.
2016
;
43
(
4
):
637
-
650
.
9.
Lisman
T
,
Porte
RJ
.
Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases
.
Res Pract Thromb Haemost
.
2017
;
1
(
2
):
150
-
161
.
10.
Levi
M
,
Sivapalaratnam
S
.
Disseminated intravascular coagulation: an update on pathogenesis and diagnosis
.
Expert Rev Hematol
.
2018
;
11
(
8
):
663
-
672
.
11.
Matsumoto
T
,
Shima
M
,
Fukuda
K
, et al
.
Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease
.
Thromb Res
.
2001
;
104
(
6
):
381
-
388
.
12.
Charlebois
J
,
Rivard
,
St-Louis
J
.
Management of acquired von Willebrand syndrome
.
Transfus Apheresis Sci
.
2018
;
57
(
6
):
721
-
723
.
13.
Franchini
M
,
Lippi
G
,
Favaloro
EJ
.
Acquired inhibitors of coagulation factors: part II
.
Semin Thromb Hemost
.
2012
;
38
(
5
):
447
-
453
.
14.
Collins
P
,
Baudo
F
,
Huth-Kühne
A
, et al
.
Consensus recommendations for the diagnosis and treatment of acquired hemophilia A
.
BMC Res Notes
.
2010
;
3
:
161
.
15.
Coppola
A
,
Favaloro
EJ
,
Tufano
A
,
Di Minno
MN
,
Cerbone
AM
,
Franchini
M
.
Acquired inhibitors of coagulation factors: part I-acquired hemophilia A
.
Semin Thromb Hemost
.
2012
;
38
(
5
):
433
-
446
.
16.
Cugno
M
,
Gualtierotti
R
,
Tedeschi
A
,
Meroni
PL
.
Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy [published correction appears in Autoimmun Rev. 2015;14(7):650]
.
Autoimmun Rev
.
2014
;
13
(
1
):
40
-
48
.
17.
Franchini
M
,
Zaffanello
M
,
Lippi
G
.
Acquired hemophilia in pediatrics: a systematic review
.
Pediatr Blood Cancer
.
2010
;
55
(
4
):
606
-
611
.
18.
Collins
PW
,
Hirsch
S
,
Baglin
TP
, et al
;
UK Haemophilia Centre Doctors’ Organisation
.
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation
.
Blood
.
2007
;
109
(
5
):
1870
-
1877
.
19.
Tengborn
L
,
Baudo
F
,
Huth-Kühne
A
, et al
;
EACH2 registry contributors
.
Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry
.
BJOG
.
2012
;
119
(
12
):
1529
-
1537
.
20.
Collins
P
,
Budde
U
,
Rand
JH
,
Federici
AB
,
Kessler
CM
.
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome
.
Haemophilia
.
2008
;
14
(
suppl 3
):
49
-
55
.
21.
Federici
AB
,
Rand
JH
,
Bucciarelli
P
, et al
;
Subcommittee on von Willebrand Factor
.
Acquired von Willebrand syndrome: data from an international registry [published correction appears in Thromb Haemost. 2000;84(4):739]
.
Thromb Haemost
.
2000
;
84
(
2
):
345
-
349
.
22.
Tiede
A
,
Priesack
J
,
Werwitzke
S
, et al
.
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study
.
J Thromb Haemost
.
2008
;
6
(
4
):
569
-
576
.
23.
Franchini
M
,
Lippi
G
.
Acquired factor V inhibitors: a systematic review
.
J Thromb Thrombolysis
.
2011
;
31
(
4
):
449
-
457
.
24.
Bowman
LJ
,
Anderson
CD
,
Chapman
WC
.
Topical recombinant human thrombin in surgical hemostasis
.
Semin Thromb Hemost
.
2010
;
36
(
5
):
477
-
484
.
25.
Kondera-Anasz
Z
.
Antibodies against fibrinogen in pregnant women, in post delivery women and in the newborns
.
Thromb Haemost
.
1998
;
79
(
5
):
963
-
968
.
26.
Dear
A
,
Brennan
SO
,
Sheat
MJ
,
Faed
JM
,
George
PM
.
Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain
.
Haematologica
.
2007
;
92
(
11
):
e111
-
e117
.
27.
Lee
N
,
Kim
JE
,
Yoo
HJ
, et al
.
Acquired dysfibrinogenemia caused by autoantibody inhibiting fibrin polymerization in a patient with MELAS syndrome and bleeding tendency
.
Ann Clin Lab Sci
.
2016
;
46
(
6
):
696
-
700
.
28.
Bänninger
H
,
Hardegger
T
,
Tobler
A
, et al
.
Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V
.
Br J Haematol
.
1993
;
85
(
3
):
528
-
532
.
29.
Ortel
TL
,
Mercer
MC
,
Thames
EH
,
Moore
KD
,
Lawson
JH
.
Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin
.
Ann Surg
.
2001
;
233
(
1
):
88
-
96
.
30.
Huang
LW
,
Anand
S
,
Hassan
S
,
Onwuemene
O
.
Bruised black and blue: acquired hypoprothrombinemia
.
Am J Med
.
2015
;
128
(
11
):
e7
-
e11
.
31.
Mulliez
SM
,
Devreese
KM
.
Isolated acquired factor VII deficiency: review of the literature
.
Acta Clin Belg
.
2016
;
71
(
2
):
63
-
70
.
32.
Kamikubo
Y
,
Miyamoto
S
,
Iwasa
A
,
Ishii
M
,
Okajima
K
.
Purification and characterization of factor VII inhibitor found in a patient with life threatening bleeding
.
Thromb Haemost
.
2000
;
83
(
1
):
60
-
64
.
33.
Mazzucconi
MG
,
Peraino
M
,
Bizzoni
L
,
Bernasconi
S
,
Luciani
M
,
Rossi
GD
.
Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone
.
Haemophilia
.
1999
;
5
(
2
):
132
-
134
.
34.
Krishnamurthy
P
,
Hawche
C
,
Evans
G
,
Winter
M
.
A rare case of an acquired inhibitor to factor IX
.
Haemophilia
.
2011
;
17
(
4
):
712
-
713
.
35.
Chan
IS
,
Ogunsile
FJ
.
An acquired factor X inhibitor: the importance of understanding coagulation
.
Am J Med
.
2017
;
130
(
7
):
e307
-
e308
.
36.
Patel
G
,
Hari
P
,
Szabo
A
, et al
.
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease
.
Hematol Oncol Stem Cell Ther
.
2019
;
12
(
1
):
10
-
14
.
37.
Furie
B
,
Greene
E
,
Furie
BC
.
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X
.
N Engl J Med
.
1977
;
297
(
2
):
81
-
85
.
38.
Rosenstein
ED
,
Itzkowitz
SH
,
Penziner
AS
,
Cohen
JI
,
Mornaghi
RA
.
Resolution of factor X deficiency in primary amyloidosis following splenectomy
.
Arch Intern Med
.
1983
;
143
(
3
):
597
-
599
.
39.
Greipp
PR
,
Kyle
RA
,
Bowie
EJ
.
Factor-X deficiency in amyloidosis: a critical review
.
Am J Hematol
.
1981
;
11
(
4
):
443
-
450
.
40.
Bortoli
R
,
Monticielo
OA
,
Chakr
RM
, et al
.
Acquired factor XI inhibitor in systemic lupus erythematosus--case report and literature review
.
Semin Arthritis Rheum
.
2009
;
39
(
1
):
61
-
65
.
41.
Ichinose
A
,
Osaki
T
,
Souri
M
;
Japanese Collaborative Research Group (JCRG) on AH13 (supported by the Japanese Ministry of Health, Labor, and Welfare)
.
Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies
.
Haemophilia
.
2015
;
21
(
5
):
653
-
658
.
42.
Yan
MTS
,
Rydz
N
,
Goodyear
D
,
Sholzberg
M
.
Acquired factor XIII deficiency: a review
.
Transfus Apheresis Sci
.
2018
;
57
(
6
):
724
-
730
.
43.
Bajaj
SP
,
Rapaport
SI
,
Barclay
S
,
Herbst
KD
.
Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management
.
Blood
.
1985
;
65
(
6
):
1538
-
1543
.
44.
Mulliez
SM
,
De Keyser
F
,
Verbist
C
, et al
.
Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature
.
Lupus
.
2015
;
24
(
7
):
736
-
745
.
45.
Tefferi
A
,
Nichols
WL
,
Bowie
EJ
.
Circulating heparin-like anticoagulants: report of five consecutive cases and a review
.
Am J Med
.
1990
;
88
(
2
):
184
-
188
.
46.
Rodgers
GM
,
Corash
L
.
Acquired heparinlike anticoagulant in a patient with metastatic breast carcinoma
.
West J Med
.
1985
;
143
(
5
):
672
-
675
.
47.
de Prost
D
,
Katlama
C
,
Pialoux
G
,
Karsenty-Mathonnet
F
,
Wolff
M
.
Heparin-like anticoagulant associated with AIDS
.
Thromb Haemost
.
1987
;
57
(
2
):
239
.
48.
Dufrost
V
,
Risse
J
,
Malgras
A
, et al
.
Unexpected cause of bleeding
.
Am J Med
.
2017
;
130
(
9
):
e387
-
e388
.
49.
Marchili
MR
,
Santoro
E
,
Marchesi
A
,
Bianchi
S
,
Rotondi Aufiero
L
,
Villani
A
.
Vitamin K deficiency: a case report and review of current guidelines
.
Ital J Pediatr
.
2018
;
44
(
1
):
36
.
50.
Forkin
KT
,
Colquhoun
DA
,
Nemergut
EC
,
Huffmyer
JL
.
The coagulation profile of end-stage liver disease and considerations for intraoperative management
.
Anesth Analg
.
2018
;
126
(
1
):
46
-
61
.
51.
Kershaw
G
,
Favaloro
EJ
.
Laboratory identification of factor inhibitors: an update
.
Pathology
.
2012
;
44
(
4
):
293
-
302
.
52.
Collins
P
,
Chalmers
E
,
Hart
D
, et al
;
United Kingdom Haemophilia Centre Doctors’ Organization
.
Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO
.
Br J Haematol
.
2013
;
162
(
6
):
758
-
773
.
53.
Baudo
F
,
Collins
P
,
Huth-Kühne
A
, et al
;
EACH2 registry contributors
.
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry
.
Blood
.
2012
;
120
(
1
):
39
-
46
.
54.
Kruse-Jarres
R
,
St-Louis
J
,
Greist
A
, et al
.
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
.
Haemophilia
.
2015
;
21
(
2
):
162
-
170
.
55.
Tarantino
MD
,
Cuker
A
,
Hardesty
B
,
Roberts
JC
,
Sholzberg
M
.
Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients
.
Haemophilia
.
2017
;
23
(
1
):
25
-
32
.
56.
Zeitler
H
,
Ulrich-Merzenich
G
,
Goldmann
G
,
Vidovic
N
,
Brackmann
HH
,
Oldenburg
J
.
The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients
.
Haemophilia
.
2010
;
16
(
102
):
95
-
101
.
57.
Oldenburg
J
,
Mahlangu
JN
,
Kim
B
, et al
.
Emicizumab prophylaxis in hemophilia A with inhibitors
.
N Engl J Med
.
2017
;
377
(
9
):
809
-
818
.
58.
Pasi
KJ
,
Rangarajan
S
,
Georgiev
P
, et al
.
Targeting of antithrombin in hemophilia A or B with RNAi therapy
.
N Engl J Med
.
2017
;
377
(
9
):
819
-
828
.
59.
Chowdary
P
,
Lethagen
S
,
Friedrich
U
, et al
.
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
.
J Thromb Haemost
.
2015
;
13
(
5
):
743
-
754
.
60.
Cardinal
M
,
Kantaridis
C
,
Zhu
T
, et al
.
A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers
.
J Thromb Haemost
.
2018
;
16
(
9
):
1722
-
1731
.
61.
Polderdijk
SG
,
Adams
TE
,
Ivanciu
L
,
Camire
RM
,
Baglin
TP
,
Huntington
JA
.
Design and characterization of an APC-specific serpin for the treatment of hemophilia
.
Blood
.
2017
;
129
(
1
):
105
-
113
.
62.
Prince
R
,
Bologna
L
,
Manetti
M
, et al
.
Targeting anticoagulant protein S to improve hemostasis in hemophilia
.
Blood
.
2018
;
131
(
12
):
1360
-
1371
.
63.
Biguzzi
E
,
Siboni
SM
,
Peyvandi
F
.
Acquired Von Willebrand syndrome and response to desmopressin
.
Haemophilia
.
2018
;
24
(
1
):
e25
-
e28
.
64.
Lavin
M
,
Ryan
K
,
White
B
,
Byrne
M
,
O’Connell
NM
,
O’Donnell
JS
.
A role for intravenous immunoglobulin in the treatment of acquired Von Willebrand syndrome associated with IgM gammopathy
.
Haemophilia
.
2018
;
24
(
1
):
e22
-
e25
.
65.
Thachil
J
,
Hay
CR
,
Campbell
S
.
Tamoxifen for recurrent bleeds due to angiodysplasia in von Willebrand’s disease
.
Haemophilia
.
2013
;
19
(
5
):
e313
-
e315
.
66.
Bowers
M
,
McNulty
O
,
Mayne
E
.
Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand’s disease
.
Br J Haematol
.
2000
;
108
(
3
):
524
-
527
.
67.
Sohal
M
,
Laffan
M
.
Von Willebrand disease and angiodysplasia responding to atorvastatin
.
Br J Haematol
.
2008
;
142
(
2
):
308
-
309
.
68.
Alikhan
R
,
Keeling
D
.
Von Willebrand disease, angiodysplasia and atorvastatin
.
Br J Haematol
.
2010
;
149
(
1
):
159
-
160
.
69.
Lim
MY
,
McCarthy
T
,
Chen
SL
,
Rollins-Raval
MA
,
Ma
AD
.
Importance of pharmacokinetic studies in the management of acquired factor X deficiency
.
Eur J Haematol
.
2016
;
96
(
1
):
60
-
64
.
70.
Thompson
CA
,
Kyle
R
,
Gertz
M
,
Heit
J
,
Pruthi
R
,
Pardanani
A
.
Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients
.
Am J Hematol
.
2010
;
85
(
3
):
171
-
173
.
71.
Franchini
M
,
Frattini
F
,
Crestani
S
,
Bonfanti
C
.
Acquired FXIII inhibitors: a systematic review
.
J Thromb Thrombolysis
.
2013
;
36
(
1
):
109
-
114
.
72.
Collins
P
,
Baudo
F
,
Knoebl
P
, et al
;
EACH2 registry collaborators
.
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
.
Blood
.
2012
;
120
(
1
):
47
-
55
.
73.
Tiede
A
,
Klamroth
R
,
Scharf
RE
, et al
.
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
.
Blood
.
2015
;
125
(
7
):
1091
-
1097
.
74.
Lavin
M
,
Brophy
TM
,
Rawley
O
, et al
.
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy
.
J Thromb Haemost
.
2016
;
14
(
6
):
1200
-
1205
.
75.
Khatri
NV
,
Patel
B
,
Kohli
DR
,
Solomon
SS
,
Bull-Henry
K
,
Kessler
CM
.
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease
.
Haemophilia
.
2018
;
24
(
2
):
278
-
282
.
You do not currently have access to this content.